RAD-140 (Testolone)
Also known as: Testolone, RAD140
Overview
RAD-140 (Testolone) is a potent, orally bioavailable nonsteroidal SARM developed by Radius Health. It demonstrates one of the highest anabolic-to-androgenic ratios (90:1) of any known androgen receptor modulator, meaning it produces strong muscle anabolic effects while displaying minimal androgenic activity at the prostate in preclinical models. RAD-140 is also being investigated for neuroprotective properties and potential application in breast cancer treatment through its AR-agonist/ER-antagonist activity.
Mechanism of Action
RAD-140 binds to the androgen receptor (AR) with high affinity (Ki ~7 nM) and acts as a full agonist in muscle and bone tissue. The compound produces a distinct AR conformation that recruits anabolic coactivators preferentially over androgenic coactivators, achieving tissue selectivity. In the brain, RAD-140 activates AR-mediated neuroprotective pathways and has demonstrated apoptosis inhibition in neurons via stimulation of MAPK signaling and BDNF expression. Additionally, RAD-140 may act as an estrogen receptor (ER) antagonist in breast cancer cells expressing both AR and ER.
Potential Benefits
- High anabolic potency with 90:1 anabolic:androgenic ratio in preclinical studies
- Significant lean muscle mass increases in primate studies
- Neuroprotective effects and BDNF upregulation
- Potential activity against AR+/ER+ breast cancer
- No conversion to estrogen or DHT (non-steroidal)
- Oral bioavailability with once-daily dosing
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 10-20 mg/day |
| Beginner | 10 mg/day |
| Intermediate | 15 mg/day |
| Advanced | 20 mg/day (some research protocols up to 30 mg but not recommended) |
| Cycle Duration | 6-8 weeks |
| Cycle Off | 8-12 weeks; post-cycle therapy required after most cycles |
Long half-life (~60 hours) means steady-state is achieved within 2 weeks. More suppressive than Ostarine — post-cycle therapy with SERMs or peptides that support HPG axis (Kisspeptin, Gonadorelin) is strongly advisable.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Oral (Capsule/Tablet) Varies — typically moderate for oral-stable compounds
Take with or without food as specified. Follow product labeling for timing.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving RAD-140 (Testolone):
Anabolic Recovery Stack
Combines RAD-140 (Testolone) with healing (BPC-157) and GH-axis support (CJC-1295 + Ipamorelin) for comprehensive muscle growth and recovery.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | N/A — oral capsules or liquid suspension (10-20mg/ml) |
|---|---|
| BAC Water | N/A — oral formulation |
| Storage | Store at room temperature 15-25°C; protect from light and moisture |
| Shelf Life | 24-36 months sealed |
Need exact syringe measurements?
Amino Acid Sequence
N/A — non-peptide small molecule SARM
Side Effects & Safety
- Significant testosterone suppression (more pronounced than Ostarine)
- Post-cycle therapy (PCT) strongly recommended
- Possible hair loss (DHT-independent mechanism via AR activation in follicles)
- Potential liver toxicity (case reports at high doses/long duration)
- Aggression and mood changes reported at high doses
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
Pharmacokinetics
| Half-Life | ~20 hours (reported range 16-60 hours) |
|---|---|
| Storage | Store liquid/capsules at room temperature in a dark, dry place. |
Synergistic Compounds
The following compounds have been studied alongside RAD-140 (Testolone) for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA Staff Reviewers Say ‘No’ to 7 Compounded Peptides Ahead of July PCAC Vote
FDA staff reviewers urged against adding seven popular peptides to the 503A bulks list ahead of the July PCAC meeting, citing weak human data and safety uncertainty.
FDA reviewers urge ‘no’ on BPC-157, TB-500, MOTS-c ahead of July 2026 compounding vote
FDA reviewers’ June 29 briefings recommend against listing seven popular peptides for 503A compounding, citing limited human data and immunogenicity risk.
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Ahead of the July 23–24 Pharmacy Compounding Advisory Committee meeting, FDA staff briefings recommend against listing seven popular peptides for compounding.